Literature DB >> 2464673

Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities.

F Adams1, F Fernandez, G Mavligit.   

Abstract

Eleven patients ranging in age from 52 to 80 years, undergoing treatment for cancer with various preparations of interferon received neurobehavioral evaluations after experiencing unexpectedly severe organic mental disorders. The reactions ranged from delirium to extrapyramidal symptoms, mania, and neurasthenia with catatonic episodes. Computed tomographic (CT) scans of the brain disclosed unsuspected pre-existing neurologic abnormalities in all patients, including cerebral atrophy (6/11), brain metastases (4/11), and evidence of head injury incurred 40 years earlier (1/11). These findings suggest that cancer patients with pre-existing neurologic dysfunctions are at increased risk for severe interferon neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2464673     DOI: 10.1007/bf00177432

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  12 in total

1.  Effect of interferon on severe psychiatric diseases.

Authors:  K Cantell; E Pulkkinen; R Elosuo; J Suominen
Journal:  Ann Clin Res       Date:  1980-06

2.  Neuralgic amyotrophy and polyradiculopathy during interferon therapy.

Authors:  P L Bernsen; R E Wong-Chung; J T Janssen
Journal:  Lancet       Date:  1985-01-05       Impact factor: 79.321

3.  Neurotoxicity of interferon.

Authors:  K Mattson; A Niiranen; M Iivanainen; M Färkkilä; L Bergström; L R Holsti; H L Kauppinen; K Cantell
Journal:  Cancer Treat Rep       Date:  1983-10

4.  Human leukocyte interferon (HuIFN-alpha): potent endorphin-like opioid activity.

Authors:  J E Blalock; E M Smith
Journal:  Biochem Biophys Res Commun       Date:  1981-07-30       Impact factor: 3.575

5.  Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies.

Authors:  E A Obbens; L G Feun; M E Leavens; N Savaraj; D J Stewart; J U Gutterman
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

6.  Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis.

Authors:  M Iivanainen; R Laaksonen; M L Niemi; M Färkkilä; L Bergström; K Mattson; A Niiranen; K Cantell
Journal:  Acta Neurol Scand       Date:  1985-11       Impact factor: 3.209

7.  Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report.

Authors:  C C Suter; B F Westmoreland; F W Sharbrough; R C Hermann
Journal:  Mayo Clin Proc       Date:  1984-12       Impact factor: 7.616

8.  Does the diagnosis of depression in head and neck cancer mask organic brain disease?

Authors:  F Adams; D L Larson; H Goepfert
Journal:  Otolaryngol Head Neck Surg       Date:  1984-12       Impact factor: 3.497

9.  Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

Authors:  F Adams; J R Quesada; J U Gutterman
Journal:  JAMA       Date:  1984-08-17       Impact factor: 56.272

10.  Central nervous system toxicity of interferon.

Authors:  A Z Rohatiner; P F Prior; A C Burton; A T Smith; F R Balkwill; T A Lister
Journal:  Br J Cancer       Date:  1983-03       Impact factor: 7.640

View more
  12 in total

1.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

2.  Effect of interferon-alpha on DOI-induced wet-dog shakes in rats.

Authors:  A Kugaya; A Kagaya; Y Uchitomi; N Yokota; S Yamawaki
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 3.  HIV Eradication Strategies: Implications for the Central Nervous System.

Authors:  Rebecca T Veenhuis; Janice E Clements; Lucio Gama
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

4.  Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.

Authors:  M Makino; Y Kitano; C Komiyama; M Hirohashi; K Takasuna
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 5.  Neurobehavioral effects of interferon therapy.

Authors:  Alan D Valentine; Christina A Meyers
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 6.  Neuropsychiatric side effects of interferon-alfa therapy.

Authors:  Arthur R Van Gool; Wim H J Kruit; Frederike K Engels; Gerrit Stoter; Marjolein Bannink; Alexander M M Eggermont
Journal:  Pharm World Sci       Date:  2003-02

Review 7.  Neuropsychiatric adverse effects of interferon-alpha: recognition and management.

Authors:  Charles L Raison; Marina Demetrashvili; Lucile Capuron; Andrew H Miller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 8.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

Review 9.  Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective.

Authors:  Krista M Rubin; Karen Vona; Kathleen Madden; Suzanne McGettigan; Ilana M Braun
Journal:  Support Care Cancer       Date:  2012-05-05       Impact factor: 3.603

10.  Systemic inflammation induces acute working memory deficits in the primed brain: relevance for delirium.

Authors:  Carol Murray; David J Sanderson; Chris Barkus; Robert M J Deacon; J Nicholas P Rawlins; David M Bannerman; Colm Cunningham
Journal:  Neurobiol Aging       Date:  2010-05-14       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.